BTIG Research restated their buy rating on shares of Galapagos (NASDAQ:GLPG) in a report published on Monday, November 20th. BTIG Research currently has a $118.00 target price on the biotechnology company’s stock.
A number of other research analysts have also recently issued reports on GLPG. Stifel Nicolaus upgraded shares of Galapagos from a hold rating to a buy rating and lifted their target price for the company from $83.00 to $101.00 in a research note on Friday, August 11th. Cowen reiterated a buy rating on shares of Galapagos in a research note on Thursday, August 10th. Morgan Stanley reiterated an overweight rating and issued a $92.00 target price on shares of Galapagos in a research note on Thursday, August 10th. BidaskClub cut shares of Galapagos from a hold rating to a sell rating in a research note on Saturday, August 5th. Finally, Zacks Investment Research raised shares of Galapagos from a sell rating to a hold rating in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $111.00.
Shares of Galapagos (GLPG) traded down $0.40 on Monday, reaching $85.07. 79,254 shares of the company’s stock were exchanged, compared to its average volume of 149,177. Galapagos has a 1 year low of $57.92 and a 1 year high of $104.12.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Federated Investors Inc. PA grew its holdings in Galapagos by 36.8% during the 2nd quarter. Federated Investors Inc. PA now owns 1,364,600 shares of the biotechnology company’s stock worth $104,419,000 after acquiring an additional 366,800 shares during the period. EcoR1 Capital LLC grew its holdings in Galapagos by 5.0% during the 2nd quarter. EcoR1 Capital LLC now owns 578,505 shares of the biotechnology company’s stock worth $44,267,000 after acquiring an additional 27,464 shares during the period. Orbimed Advisors LLC grew its holdings in Galapagos by 84.8% during the 3rd quarter. Orbimed Advisors LLC now owns 523,790 shares of the biotechnology company’s stock worth $53,296,000 after acquiring an additional 240,290 shares during the period. Renaissance Technologies LLC grew its holdings in Galapagos by 49.5% during the 2nd quarter. Renaissance Technologies LLC now owns 465,300 shares of the biotechnology company’s stock worth $35,605,000 after acquiring an additional 154,100 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Galapagos by 0.6% during the second quarter. Goldman Sachs Group Inc. now owns 202,173 shares of the biotechnology company’s stock worth $15,471,000 after purchasing an additional 1,235 shares in the last quarter. 19.71% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Galapagos (NASDAQ:GLPG) Given “Buy” Rating at BTIG Research” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/07/btig-research-reiterates-buy-rating-for-galapagos-nv-glpg.html.
Galapagos Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.